Understanding graft-induced dyskinesia

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Parkinson J: An Essay On The Shaking Palsy. Sherwood, Neely and Jones, London, UK (1817).
  Google Scholar
• 2  Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5,235–245 (2006).
  MedlineGoogle Scholar
• 3  Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16,448–458 (2001).
  Medline CASGoogle Scholar
• 4  Muller T, Russ H: Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin. Pharmacother.7,1715–1730 (2006).
  MedlineGoogle Scholar
• 5  Cenci MA, Lindgren HS: Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol.17,665–671 (2007).
  Medline CASGoogle Scholar
• 6  Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A: Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat. Disord.14(Suppl. 2),S154–S158 (2008).
  MedlineGoogle Scholar
• 7  Brundin P, Nilsson OG, Strecker RE et al.: Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp. Brain Res.65,235–240 (1986).
  Medline CASGoogle Scholar
• 8  Bjorklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD: Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res.199,307–333 (1980).
  Medline CASGoogle Scholar
• 9  Nadaud D, Herman JP, Simon H, Le Moal M: Functional recovery following transplantation of ventral mesencephalic cells in rat subjected to 6-OHDA lesions of the mesolimbic dopaminergic neurons. Brain Res.304,137–141 (1984).
  Medline CASGoogle Scholar
• 10  Backlund EO, Granberg PO, Hamberger B et al.: Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg.62,169–173 (1985).
  Medline CASGoogle Scholar
• 11  Markham CM, Rand RW, Jacques DB et al.: Transplantation of fetal mesencephalic tissue in Parkinson’s patients. Stereotact. Funct. Neurosurg.62,134–140 (1994).
  Medline CASGoogle Scholar
• 12  Peschanski M, Defer G, N’Guyen JP et al.: Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson’s disease following intrastriatal transplantation of fetal ventral mesencephalon. Brain117(Pt 3),487–499 (1994).
  MedlineGoogle Scholar
• 13  Freeman TB, Olanow CW, Hauser RA et al.: Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson’s disease. Ann. Neurol.38,379–388 (1995).
  Medline CASGoogle Scholar
• 14  Defer GL, Geny C, Ricolfi F et al.: Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain119(Pt 1),41–50 (1996).
  MedlineGoogle Scholar
• 15  Kopyov OV, Jacques DS, Lieberman A, Duma CM, Rogers RL: Outcome following intrastriatal fetal mesencephalic grafts for Parkinson’s patients is directly related to the volume of grafted tissue. Exp. Neurol.146,536–545 (1997).
  Medline CASGoogle Scholar
• 16  Kordower JH, Freeman TB, Chen EY et al.: Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Mov. Disord.13,383–393 (1998).
  Medline CASGoogle Scholar
• 17  Lindvall O: Update on fetal transplantation: the Swedish experience. Mov. Disord.13(Suppl. 1),83–87 (1998).
  MedlineGoogle Scholar
• 18  Freed CR, Greene PE, Breeze RE et al.: Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med.344,710–719 (2001).▪▪ First full report of graft-induced dyskinesia following transplantation in a double-blind, placebo-controlled study.
  Medline CASGoogle Scholar
• 19  Olanow CW, Goetz CG, Kordower JH et al.: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol.54,403–414 (2003).
  MedlineGoogle Scholar
• 20  Greene P, Fahn S, Tsai WY et al.: Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson’s disease. Mov. Disord.14,904 (1999).▪ First report of graft-induced dyskinesia in patients after transplantation.
  Google Scholar
• 21  Hagell P, Piccini P, Bjorklund A et al.: Dyskinesias following neural transplantation in Parkinson’s disease. Nat. Neurosci.5,627–628 (2002).
  Medline CASGoogle Scholar
• 22  Piccini P, Pavese N, Hagell P et al.: Factors affecting the clinical outcome after neural transplantation in Parkinson’s disease. Brain128,2977–2986 (2005).▪▪ Clinical examination of the factors influencing the success of transplantation in the Lund cohort.
  MedlineGoogle Scholar
• 23  Olanow CW, Gracies JM, Goetz CG et al.: Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double blind video-based analysis. Mov. Disord.24,336–343 (2009).▪▪ Clinical examination of the factors influencing the success of transplantation in the Tampa–Mount Sinai cohort.
  MedlineGoogle Scholar
• 24  Freed C, Breeze R, Fahn S, Eidelberg D: Preoperative response to levodopa in the best predictor of transplant outcome. Ann. Neurol.55,896; author reply 896–897 (2004).
  MedlineGoogle Scholar
• 25  Cho C, Alterman R, Miravite J, Shils J, Taglati M: Subthalamic DBS for the treatment of ‘runaway’ dyskinesias after embryonic or fetal tissue transplant. Mov. Disord.20,1237 (2005).
  Google Scholar
• 26  Herzog J, Pogarell O, Pinsker MO et al.: Deep brain stimulation in Parkinson’s disease following fetal nigral transplantation. Mov. Disord.23,1293–1296 (2008).
  MedlineGoogle Scholar
• 27  Ma Y, Feigin A, Dhawan V et al.: Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol.52,628–634 (2002).
  MedlineGoogle Scholar
• 28  Winkler C, Kirik D, Bjorklund A: Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci.28,86–92 (2005).
  Medline CASGoogle Scholar
• 29  Goetz CG, Stebbins GT, Blasucci LM, Grobman MS: Efficacy of a patient-training videotape on motor fluctuations for on–off diaries in Parkinson’s disease. Mov. Disord.12,1039–1041 (1997).
  Medline CASGoogle Scholar
• 30  Cenci MA, Hagell P: Dyskinesia and neural grafting in Parkinson’s disease. In: Restorative Therapies In Parkinson’s Disease. Brundin P, Olanow W (Eds). Kluwer Academic/Plenum Publishers, NY, USA, 184–224 (2006).
  Google Scholar
• 31  Langston JW, Ballard P: Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can. J. Neurol. Sci.11,160–165 (1984).
  Medline CASGoogle Scholar
• 32  Cenci MA, Lee CS, Bjorklund A: L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci.10,2694–2706 (1998).
  Medline CASGoogle Scholar
• 33  Redmond DE, Vinuela A, Kordower JH, Isacson O: Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease. Neurobiol. Dis.29,103–116 (2008).
  Medline CASGoogle Scholar
• 34  Lane EL, Winkler C, Brundin P, Cenci MA: The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis.22,334–345 (2006).
  Medline CASGoogle Scholar
• 35  Vinuela A, Hallett PJ, Reske-Nielsen C et al.: Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson’s disease. Brain131,3361–3379 (2008).
  Medline CASGoogle Scholar
• 36  Steece-Collier K, Collier TJ, Danielson PD et al.: Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov. Disord.18,1442–1454 (2003).
  MedlineGoogle Scholar
• 37  Maries E, Kordower JH, Chu Y et al.: Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol. Dis.21,165–180 (2006).
  MedlineGoogle Scholar
• 38  Soderstrom KE, Meredith G, Freeman TB et al.: The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol. Dis.32,229–242 (2008).
  Medline CASGoogle Scholar
• 39  Steece-Collier K, Soderstrom KE, Collier TJ, Sortwell CE, Maries-Lad E: Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J. Comp. Neurol.515,15–30 (2009).
  Medline CASGoogle Scholar
• 40  Lane EL, Soulet D, Vercammen L, Cenci MA, Brundin P: Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson’s disease. Neurobiol. Dis.32,220–228 (2008).
  Medline CASGoogle Scholar
• 41  Lane EL, Brundin P, Cenci MA: Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson’s disease. Neurobiol. Dis.35,42–51 (2009).
  Medline CASGoogle Scholar
• 42  Lane EL, Vercammen L, Cenci MA, Brundin P: Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp. Neurol.219,255–258 (2009).
  Google Scholar
• 43  Carlsson T, Winkler C, Lundblad M et al.: Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis.21,657–668 (2006).▪ First report of amphetamine-induced abnormal involuntary movements in the rodent model.
  Medline CASGoogle Scholar
• 44  Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D: Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease. J. Neurosci.27,8011–8022 (2007).
  Medline CASGoogle Scholar
• 45  Cenci MA, Lundblad M: Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice. Curr. Protoc. Neurosci. Chapter 9, Unit 9, 25 (2007).
  MedlineGoogle Scholar
• 46  Winkler C, Kirik D, Bjorklund A, Cenci MA: L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis.10,165–186 (2002).
  MedlineGoogle Scholar
• 47  Lee CS, Cenci MA, Schulzer M, Bjorklund A: Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain123(Pt 7),1365–1379 (2000).
  MedlineGoogle Scholar
• 48  Gaudin DP, Rioux L, Bedard PJ: Fetal dopamine neuron transplants prevent behavioral supersensitivity induced by repeated administration of L-dopa in the rat. Brain Res.506,166–168 (1990).
  Medline CASGoogle Scholar
• 49  Carlsson T, Carta M, Munoz A et al.: Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain132,319–335 (2009).
  MedlineGoogle Scholar
• 50  Kuan WL, Lin R, Tyers P, Barker RA: The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol. Dis.25,594–608 (2007).
  Medline CASGoogle Scholar
• 51  Jacques DB, Kopyov OV, Eagle KS, Carter T, Lieberman A: Outcomes and complications of fetal tissue transplantation in Parkinson’s disease. Stereotact. Funct. Neurosurg.72,219–224 (1999).
  Medline CASGoogle Scholar
• 52  Ungerstedt U: Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl.367,49–68 (1971).
  Medline CASGoogle Scholar
• 53  Ungerstedt U, Arbuthnott GW: Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res.24,485–493 (1970).
  Medline CASGoogle Scholar
• 54  Herman JP, Rouge-Pont F, Le Moal M, Abrous DN: Mechanisms of amphetamine-induced rotation in rats with unilateral intrastriatal grafts of embryonic dopaminergic neurons: a pharmacological and biochemical analysis. Neuroscience53,1083–1095 (1993).
  Medline CASGoogle Scholar
• 55  Torres EM, Dunnett SB: Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson’s disease. Eur. Neuropsychopharmacol.17,206–214 (2007).
  Medline CASGoogle Scholar
• 56  Kelley AE, Lang CG, Gauthier AM: Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology95,556–559 (1988).
  Medline CASGoogle Scholar
• 57  Brown LL, Sharp FR: Metabolic mapping of rat striatum: somatotopic organization of sensorimotor activity. Brain Res.686,207–222 (1995).
  Medline CASGoogle Scholar
• 58  Brown LL: Somatotopic organization in rat striatum: evidence for a combinational map. Proc. Natl Acad. Sci. USA89,7403–7407 (1992).
  Medline CASGoogle Scholar
• 59  Munoz A, Carlsson T, Tronci E et al.: Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol.219,298–307 (2009).
  Medline CASGoogle Scholar
• 60  Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A: Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res.172,465–478 (2008).
  Medline CASGoogle Scholar
• 61  Mendez I, Vinuela A, Astradsson A et al.: Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat. Med.14,507–509 (2008).
  Medline CASGoogle Scholar
• 62  Carlsson T, Carta M, Munoz A et al.: Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain132,319–335 (2008).
  MedlineGoogle Scholar
• 63  Carta M, Carlsson T, Kirik D, Bjorklund A: Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain130,1819–1833 (2007).
  MedlineGoogle Scholar
• 64  Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM: Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease. Exp. Neurol.183,458–468 (2003).
  Medline CASGoogle Scholar
• 65  Picconi B, Centonze D, Hakansson K et al.: Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci.6,501–506 (2003).
  Medline CASGoogle Scholar
• 66  Cenci MA, Tranberg A, Andersson M, Hilbertson A: Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience94,515–527 (1999).
  Medline CASGoogle Scholar
• 67  Blunt SB, Jenner P, Marsden CD: Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving fetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Res.582,299–311 (1992).
  Medline CASGoogle Scholar
• 68  Andersson M, Hilbertson A, Cenci MA: Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol. Dis.6,461–474 (1999).
  Medline CASGoogle Scholar
• 69  Cenci MA, Campbell K, Bjorklund A: Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience57,275–296 (1993).
  Medline CASGoogle Scholar
• 70  Roy E, Cote PY, Gregoire L, Parent A, Bedard PJ: Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine. Neuroscience66,413–425 (1995).
  Medline CASGoogle Scholar
• 71  Yu TS, Wang SD, Liu JC, Yin HS: Changes in the gene expression of GABA_A receptor α-1 and α-2 subunits and metabotropic glutamate receptor 5 in the basal ganglia of the rats with unilateral 6-hydroxydopamine lesion and embryonic mesencephalic grafts. Exp. Neurol.168,231–241 (2001).
  Medline CASGoogle Scholar
• 72  Rodriguez-Pallares J, Caruncho HJ, Munoz A, Guerra MJ, Labandeira-Garcia JL: GABAA receptor subunit expression in intrastriatal ventral mesencephalic transplants. Exp. Brain Res.135,331–340 (2000).
  Medline CASGoogle Scholar
• 73  Chritin M, Savasta M, Mennicken F et al.: Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptor mRNA levels caused by lesion of the nigrostriatal pathway: a quantitative in situ hybridization study. Eur. J. Neurosci.4,663–672 (1992).
  MedlineGoogle Scholar
• 74  Abrous DN, Torres EM, Annett LE, Reading PJ, Dunnett SB: Intrastriatal dopamine-rich grafts induce a hyperexpression of Fos protein when challenged with amphetamine. Exp. Brain Res.91,181–190 (1992).
  Medline CASGoogle Scholar
• 75  Cenci MA, Bjorklund A: Transection of corticostriatal afferents abolishes the hyperexpression of Fos and counteracts the development of rotational overcompensation induced by intrastriatal dopamine-rich grafts when challenged with amphetamine. Brain Res.665,167–174 (1994).
  Medline CASGoogle Scholar
• 76  Brodsky MA, Hogarth P, Nutt JG: OFF–off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson’s disease. Mov. Disord.21,1487–1490 (2006).
  MedlineGoogle Scholar
• 77  Merello M, Perez-Lloret S, Antico J, Obeso JA: Dyskinesias induced by subthalamotomy in Parkinson’s disease are unresponsive to amantadine. J. Neurol. Neurosurg. Psychiatry77,172–174 (2006).
  Medline CASGoogle Scholar
• 78  Schupbach WM, Chastan N, Welter ML et al.: Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry76,1640–1644 (2005).
  Medline CASGoogle Scholar
• 79  Thobois S, Mertens P, Guenot M et al.: Subthalamic nucleus stimulation in Parkinson’s disease: clinical evaluation of 18 patients. J. Neurol249,529–534 (2002).
  Medline CASGoogle Scholar
• 80  Hagell P, Brundin P: Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol.60,741–752 (2001).
  Medline CASGoogle Scholar
• 81  Holden C: Neuroscience. Fetal cells again? Science326,358–359 (2009).
  Medline CASGoogle Scholar
• 82  Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131,861–872 (2007).▪ First report of human induced pluripotent stem cells.
  Medline CASGoogle Scholar
• 83  Andersson E, Tryggvason U, Deng Q et al.: Identification of intrinsic determinants of midbrain dopamine neurons. Cell124,393–405 (2006).
  Medline CASGoogle Scholar
• 84  Li JY, Christophersen NS, Hall V, Soulet D, Brundin P: Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci.31,146–153 (2008).
  MedlineGoogle Scholar
• 85  Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL: Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson’s disease. Cell Transplant5,327–337 (1996).
  Medline CASGoogle Scholar